Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. (NASDAQ: ALLO) is a clinical-stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for treating cancer and autoimmune diseases. The company's website is www.allogene.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Allogene Therapeutics, Inc. does
In the company’s own words
Allogene Therapeutics, Inc. (NASDAQ: ALLO) is a clinical-stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for treating cancer and autoimmune diseases. The company's website is www.allogene.com.
The company develops off-the-shelf T cell therapies derived from healthy donors for use in any eligible patient, rather than autologous approaches requiring individual patient cell collection and manufacturing. This allogeneic strategy aims to deliver treatments faster, more reliably, and at greater scale than traditional autologous therapies. Allogene's approach involves engineering T cells to minimize graft-versus-host disease risk through genetic modifications that eliminate functional T cell receptors, while incorporating chimeric antigen receptors designed to target specific cancer cells or pathogenic immune cells.
Allogene's pipeline focuses on three core programs. Cemacabtagene ansegedleucel, or cema-cel, targets CD19 for large B-cell lymphoma treatment and is being evaluated in the pivotal Phase 2 ALPHA3 trial as a first-line consolidation therapy for newly diagnosed patients with minimal residual disease. ALLO-316 targets CD70 for renal cell carcinoma and received Regenerative Medicine Advanced Therapy designation in 2024. ALLO-329, targeting both CD19 and CD70, is in development for autoimmune diseases including systemic lupus erythematosus, idiopathic inflammatory myopathies, and systemic sclerosis.
The company operates Cell Forge 1, a current good manufacturing practices facility in Newark, California, for manufacturing product candidates used in clinical studies. Allogene has established strategic partnerships including an exclusive worldwide oncology license from Cellectis for TALEN gene-editing technology, a non-exclusive license from Arbor Biotechnologies for CRISPR-based gene-editing technology, and an exclusive license and collaboration agreement with Servier for developing and commercializing cema-cel in the United States, European Union, and United Kingdom.
Founded with leadership from executives previously instrumental in developing Yescarta at Kite Pharma, Allogene has treated more than 200 patients across six clinical studies. The company anticipates multiple clinical readouts in the second quarter of 2026 that could validate key scientific assumptions underlying off-the-shelf CAR T therapy.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1737287
- SIC
- 2836
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Allogene Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Allogene Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Allogene Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Allogene Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Allogene Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”